LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
The objective of this protocol is to confirm the efficacy and safety profile of Lantus in
 every day medical practice, in type 2 diabetic patients, have been treated with any other
 insulin but who did not reach the target of A1c = 7%.
Inclusion Criteria:

 -  Patients with type 2 diabetes mellitus,

 -  Having been treated with any other insulin, but who did not reach the target of
 A1c=7%.

 -  Ability and willingness to perform Self Monitoring Blood Glucose measurement

 Exclusion Criteria:

 -  Will follow the prescribing information (Summary of Product Characteristics).

 The above information is not intended to contain all considerations relevant to a patient's
 potential participation in a clinical trial.